SylviaAdamsMD

Oncology • New York, NY

Breast Cancer

Professor, Medicine, New York University School of Medicine

Join to view full profile

Dr. Adams is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Adams' full profile

Already have an account?

Office
160 East 34th Street
4th Floor
New York, NY 10016
Phone+1 212-731-5795
Is this information wrong?

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
NYU Long Island School of MedicineResidency, Internal Medicine, 1997 - 2000
Friedrich-Schiller-Universität JenaClass of 1995

Certifications & Licensure

NY State Medical License 2000 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine Start of enrollment: 2005 Jul 01
Completed
Phase 1
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) Start of enrollment: 2005 Aug 24
Completed
Phase 1
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors Start of enrollment: 2006 Mar 21
Completed
Phase 1
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases Start of enrollment: 2009 May 01
Completed
Phase 2
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer Start of enrollment: 2009 Mar 06
Completed
Phase 1, Phase 2
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
Completed
Phase 1, Phase 2
Exemestane and Cyclophosphamide for Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer Start of enrollment: 2016 Jun 01
Active, not recruiting
Phase 2
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches.
Elad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, Sylvia Adams, Brandon Santhumayor, Ying Meng, Zane Schnurman, Bernadine R Donahue, Kenneth Bernstein...> ;Journal of Neuro-Oncology. 2024 Apr 17
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast C...
Chowdhury Arif Jahangir, David B Page, Glenn Broeckx, Claudia A Gonzalez, Caoimbhe Burke, Clodagh Murphy, Jorge S Reis-Filho, Amy Ly, Paul W Harms, Rajarsi R Gupta, Mi...> ;The Journal of Pathology. 2024 Mar 1
Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
Camille Hardy-Abeloos, Julie Xiao, Cheongeun Oh, David Barbee, Bhartesh Shah, Olivier Maisonet, Carmen Perez, Sylvia Adams, Freya Schnabel, Deborah Axelrod, Amber Guth...> ;Breast Cancer Research and Treatment. 2024 Apr 1
1 citations
Long-term Survival From Breast Cancer Brain Metastases in the Era of Modern Systemic Therapies.
Elad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, Kenneth Bernstein, Bernadine R Donahue, Zane Schnurman, Jason Gurewitz, Lauren E Rotman, Sylvia Adam...> ;Neurosurgery. 2024 Jan 1
6 citations
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group...
Jeppe Thagaard, Glenn Broeckx, David B Page, Chowdhury Arif Jahangir, Sara Verbandt, Zuzana Kos, Rajarsi Gupta, Reena Khiroya, Khalid Abduljabbar, Gabriela Acosta Haab...> ;The Journal of Pathology. 2023 Aug 1
10 citations
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on...
David B Page, Glenn Broeckx, Chowdhury Arif Jahangir, Sara Verbandt, Rajarsi R Gupta, Jeppe Thagaard, Reena Khiroya, Zuzana Kos, Khalid Abduljabbar, Gabriela Acosta Ha...> ;The Journal of Pathology. 2023 Aug 1
3 citations
A Case of Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Metaplastic Breast Cancer.
Anita Gul, J Jaime Alberty-Oller, Jagbir Sandhu, Everick Ayala-Bustamante, Sylvia Adams> ;JCO Precision Oncology. 2023 May 1
10 citations
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory An...
Sherene Loi, Roberto Salgado, Peter Schmid, Javier Cortes, David W Cescon, Eric P Winer, Deborah L Toppmeyer, Hope S Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji ...> ;JCO Precision Oncology. 2023 Apr 1
2 citations
Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ.
Farbod Darvishian, Yinxiang Wu, Ugur Ozerdem, Jennifer Chun, Sylvia Adams, Amber Guth, Deborah Axelrod, Richard Shapiro, Andrea B Troxel, Freya Schnabel, Daniel Roses> ;Breast. 2022 Aug 1
28 citations
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.
Chewei Anderson Chang, Jayu Jen, Shaowen Jiang, Azin Sayad, Arvind Singh Mer, Kevin R Brown, Allison M L Nixon, Avantika Dhabaria, Kwan Ho Tang, David Venet, Christos ...> ;Cancer Discovery. 2022 Apr 1
Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic.
Douglas K Marks, Nibash Budhathoki, John Kucharczyk, Faisal Fa'ak, Nina D'Abreo, Maryann Kwa, Magdalena Plasilova, Shubhada Dhage, Phyu Phyu Soe, Daniel Becker, Alexan...> ;The Oncologist. 2022 Mar 4
29 citations
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.
Sherene Loi, Roberto Salgado, Sylvia Adams, Giancarlo Pruneri, Prudence A Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Dema...> ;NPJ Breast Cancer. 2022 Jan 11
95 citations
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
Khalid El Bairi, Harry R Haynes, Elizabeth F Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Mas...> ;NPJ Breast Cancer. 2021 Dec 1
8 citations
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall...
L A Emens, S Adams, C H Barrios, V Diéras, H Iwata, S Loi, H S Rugo, A Schneeweiss, E P Winer, S Patel, V Henschel, A Swat, M Kaul, L Molinero, S Patel, S Y Chui, P Sc...> ;Annals of Oncology. 2021 Dec 1
33 citations
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade ...
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J Haley, Anna Maria Storniolo, Mridula P ...> ;Clinical Cancer Research. 2021 Oct 29
102 citations
Activating a collaborative innate-adaptive immune response to control metastasis.
Lijuan Sun, Tim Kees, Ana S. Almeida, Bodu Liu, Xue-Yan He, David Ng, Xiao Han, David L. Spector, Iain A. McNeish, Phyllis A. Gimotty, Sylvia Adams, Mikala Egeblad> ;Cancer Cell. 2021 Oct 11
1 citations
RE: Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
Natalie Klar, Sylvia Adams> ;Journal of the National Cancer Institute. 2021 Aug 16
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall s...
L A Emens, S Adams, C H Barrios, V Diéras, H Iwata, S Loi, H S Rugo, A Schneeweiss, E P Winer, S Patel, V Henschel, A Swat, M Kaul, L Molinero, S Patel, S Y Chui, P Sc...> ;Annals of Oncology. 2021 Oct 1
42 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Leisha A. Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L. Disis, Margaret E. Gatti-Mays, Alice Y. Ho, Kevin Kalinsky, Heather L. McArthur, Elizabeth A. Mittendorf,...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
184 citations
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Diéras, H. Iwata, Sherene Loi, Hope S. Rugo, Andreas Schneeweiss, EP Winer, Sheetal Patel, Volkmar Henschel...> ;Annals of Oncology. 2021 Aug 1
91 citations
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
Sherene Loi, Stefan Michiels, Sylvia Adams, S. Loibl, Jan Budczies, Carsten Denkert, Roberto Salgado> ;Annals of Oncology. 2021 Oct 1
78 citations
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Hope S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Diéras, Eric P. Winer, Mark M. Kockx, Dieter Pee...> ;Journal of the National Cancer Institute. 2021 Jun 7
A case report of COVID-19 in an asymptomatic patient with newly diagnosed breast cancer
Cindy Cen, Maria C. Shiau, Sylvia Adams, Freya Schnabel, Amber A. Guth> ;Clinical Case Reports. 2021 Jun 1
12 citations
Multinuclear MRI to disentangle intracellular sodium concentration and extracellular volume fraction in breast cancer.
Carlotta Ianniello, Linda Moy, Justin Fogarty, Freya Schnabel, Sylvia Adams, Deborah Axelrod, Leon Axel, Ryan Brown, Guillaume Madelin> ;Scientific Reports. 2021 Mar 4
154 citations
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiss, Véronique Diéras, Hiroji Iwata, Carlos H. Barrios, Marina Nechaeva, Anh Nguyen-Duc, ...> ;Journal of the National Cancer Institute. 2021 Aug 2
Join now to see all

Journal Articles

Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study
M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Amreen Husain, Sylvia Adams, Hope S Rugo, Carlos H Barrios, Eric P Winer, The New England Journal of Medicine

Lectures

Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTN...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

SABCS Highlights in Triple-negative Breast CancerDecember 9th, 2022
Breast Cancer Drug Shows Promise, Opens New Treatment Possibilities to Thousands of PatientsJune 6th, 2022
Researchers: Breast Cancer Drug Could Help More PatientsJune 6th, 2022
Join now to see all